Facebook
Twitter
LinkedIn
ForwardWebinar: Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics (2020)
Course Director: Kelly L. Stratton, MD
This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting.
Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.
Acknowledgements:
This educational activity is supported by independent educational grants from:
- Astellas
- AstraZeneca
- Bristol-Myers Squibb
- Genentech
- Merck
- Pfizer, Inc.
- Sanofi Genzyme
Target Audience
- Urologists
- Residents
- Advanced Practice Providers (Nurse Practitioners and Physician Assistants)
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
- Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients.
- Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.
- Describe advances in genomic testing and personalized medicine for urologic cancers.
- Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.
Scientific Agenda
Welcome & Housekeeping
AUA
Pre-test
AUA/Kelly Stratton, MD
Faculty and Course Introduction
Kelly Stratton, MD
Associate Professor of Urologic Oncology
University of Oklahoma, Stephenson Cancer Center
Multi-Disciplinary Approach to Prostate Cancer
Alicia Morgans, MD, MPH
Associate Professor of Medicine, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Multidisciplinary Care for Metastatic Castrate Resistant Prostate Cancer
Kelvin A. Moses, MD, PhD, FACS
Associate Professor of Urology
Vanderbilt University Medical Center
Adjuvant treatments and Multidisciplinary Management of mRCC
Brian Shuch, MD
Associate Professor of Urology
Director, UCLA Kidney Cancer Program
Multidisciplinary Care for Bladder Cancer
Kelly Stratton, MD
Q&A
All Faculty
Wrap Up/Reminders
Kelly Stratton, MD/AUA
Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics (2020) will be held virtually on Tuesday, September 1 at 7 PM EST.
***Instructions***
- Click the "Register" tab.
- If prompted, click “update your profile”. Otherwise, click “Take Course”.
- Click “Start” under Live Webinar in the Course Progress pane.
- Click "Join Webinar".
Education Council Disclosures
Education Council & COI Reviewer Disclosure_090120.pdf
AUA Office of Education Staff has nothing to disclose.
Kelly Stratton, MD
Alicia Morgans, MD
Kelvin Moses, MD, PHD
Brian Shuch, MD
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA Participant Information and Policies
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:
The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
SPECIAL ASSISTANCE/DIETARY NEEDS:
The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation